Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

CAPR

Capricor Therapeutics Inc

Oct 04 • 04:00PM ET

21.65

Dollar change +4.58
Percentage change 26.83	%

Healthcare • Biotechnology • USA • NASD

Held by: IWM IWO VTI VXF IWC IWN VTWO RSSL VTWG URTY

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.93	Insider Own	16.78%	Shs Outstand	31.15M	Perf Week	117.59%
Market Cap	704.49M	Forward P/E	-	EPS next Y	-0.71	Insider Trans	105.14%	Shs Float	27.08M	Perf Month	410.61%
Income	-27.95M	PEG	-	EPS next Q	-0.36	Inst Own	19.92%	Short Float	27.79%	Perf Quarter	353.88%
Sales	27.15M	P/S	25.95	EPS this Y	-47.71%	Inst Trans	37.70%	Short Ratio	3.49	Perf Half Y	222.17%
Book/sh	0.36	P/B	60.20	EPS next Y	41.92%	ROA	-66.31%	Short Interest	7.53M	Perf Year	662.32%
Cash/sh	0.91	P/C	23.91	EPS next 5Y	-	ROE	-392.69%	52W Range	2.68 - 18.14	Perf YTD	342.74%
Dividend Est.	-	P/FCF	-	EPS past 5Y	30.59%	ROI	-175.51%	52W High	19.35%	Beta	4.04
Dividend TTM	-	Quick Ratio	1.37	Sales past 5Y	339.72%	Gross Margin	95.31%	52W Low	707.84%	ATR (14)	1.83
Dividend Ex-Date	-	Current Ratio	1.37	EPS Y/Y TTM	20.22%	Oper. Margin	-109.70%	RSI (14)	94.61	Volatility	29.95% 15.81%
Employees	102	Debt/Eq	0.45	Sales Y/Y TTM	187.15%	Profit Margin	-102.93%	Recom	1.00	Target Price	34.40
Option/Short	Yes / Yes	LT Debt/Eq	0.38	EPS Q/Q	-18.78%	Payout	-	Rel Volume	4.65	Prev Close	17.07
Sales Surprise	-13.29%	EPS Surprise	1.69%	Sales Q/Q	1.38%	Earnings	Aug 07 AMC	Avg Volume	2.16M	Price	21.65
SMA20	171.78%	SMA50	279.58%	SMA200	311.27%	Trades		Volume	10,016,404	Change	26.83%

Date	Action	Analyst	Rating Change	Price Target Change
May-17-24	Initiated	Oppenheimer	Outperform	$14
Jan-05-24	Initiated	Cantor Fitzgerald	Overweight	$8
Oct-26-22	Initiated	Ladenburg Thalmann	Buy	$15
Dec-26-18	Downgrade	Maxim Group	Buy → Hold
Jan-26-18	Reiterated	H.C. Wainwright	Buy	$6.50 → $8.60
Sep-15-17	Reiterated	H.C. Wainwright	Buy	$2.15 → $6.50
Feb-13-17	Resumed	Rodman & Renshaw	Buy	$14
Jul-06-16	Resumed	H.C. Wainwright	Buy	$13
Jun-15-16	Initiated	ROTH Capital	Buy

Oct-04-24 09:15AM	Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress (GlobeNewswire) +26.83%
Oct-03-24 05:07AM	Is Capricor Therapeutics, Inc. (CAPR) the Best Russell 2000 Stock to Buy According to Analysts? (Insider Monkey)
Sep-24-24 08:00AM	Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy (GlobeNewswire) +52.43%
07:37AM	Capricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains? (Zacks)
Sep-23-24 09:25AM	Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024 (GlobeNewswire) +18.22%
09:15AM	Loading…
Sep-17-24 09:15AM	Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire) +15.19%
09:07AM	EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm (Benzinga)
Sep-06-24 08:30AM	Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences (GlobeNewswire)
Aug-07-24 05:25PM	Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -8.95% +8.99%
04:22PM	Capricor: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-31-24 09:00AM	Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7 (GlobeNewswire)
Jul-01-24 09:00AM	Capricor Therapeutics Set to Join Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
06:12AM	Capricors cell therapy shows three year benefit in DMD patients (Clinical Trials Arena)
Jun-28-24 09:00AM	Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy (GlobeNewswire)
10:30AM	Loading…
Jun-25-24 10:30AM	CORRECTION: Capricor Therapeutics (GlobeNewswire)
08:30AM	Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Jun-11-24 09:25AM	Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway (GlobeNewswire)
Jun-10-24 09:38AM	Capricor (CAPR) Advances in DMD Therapy With Positive Study Data (Zacks)
Jun-04-24 09:00AM	Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy (GlobeNewswire)
May-17-24 07:59AM	Oppenheimer Initiates Capricor Therapeutics at Outperform Rating (MT Newswires) +9.93%
May-14-24 08:20AM	Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:04AM	Capricor Therapeutics Inc (CAPR) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-13-24 09:54PM	CAPR Stock Earnings: Capricor Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:15PM	Capricor Therapeutics (CAPR) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:17PM	Capricor: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-24 09:15AM	Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting (GlobeNewswire)
May-08-24 09:00AM	Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences (GlobeNewswire)
May-06-24 09:00AM	Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13 (GlobeNewswire)
03:21PM	Loading…
Apr-24-24 03:21PM	Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug (MT Newswires)
09:00AM	Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy (GlobeNewswire)
Apr-10-24 09:55AM	Wall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should Know (Zacks)
Mar-25-24 09:55AM	How Much Upside is Left in Capricor (CAPR)? Wall Street Analysts Think 229.15% (Zacks)
Mar-21-24 08:30AM	Capricor Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Mar-07-24 09:55AM	Can Capricor (CAPR) Climb 261.27% to Reach the Level Wall Street Analysts Expect? (Zacks)
Mar-06-24 08:30AM	Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (GlobeNewswire)
Mar-02-24 08:17AM	Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-01-24 06:06AM	Q4 2023 Capricor Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +8.69%
Feb-29-24 04:42PM	Capricor Therapeutics Inc (CAPR) Reports Encouraging Year-End Financials and Advances in DMD Therapy (GuruFocus.com)
04:35PM	Capricor: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-27-24 08:30AM	Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy (GlobeNewswire) +9.60%
Feb-22-24 08:30AM	Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29 (GlobeNewswire)
Feb-20-24 08:30AM	Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization (GlobeNewswire) +6.37%
Jan-24-24 09:15AM	Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2 (GlobeNewswire)
Dec-11-23 09:00AM	Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis (GlobeNewswire)
Nov-16-23 08:28AM	Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 04:30PM	Capricor: Q3 Earnings Snapshot (Associated Press Finance) +5.99% +6.64%
04:05PM	Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-23 09:15AM	Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14 (GlobeNewswire)
Nov-02-23 10:00AM	Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline (Zacks)
Oct-25-23 09:35AM	After Plunging -52.01% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR) (Zacks)
Oct-24-23 09:35AM	After Plunging -50.99% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR) (Zacks)
Oct-19-23 04:01PM	Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program (GlobeNewswire)
Oct-10-23 09:00AM	Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society (GlobeNewswire)
Sep-29-23 07:35AM	Capricor Therapeutics Announces $23 Million Registered Direct Offering (GlobeNewswire) -41.19%
07:30AM	Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy (GlobeNewswire)
Sep-06-23 09:00AM	Capricor Therapeutics Appoints Michael Kelliher to Board of Directors (GlobeNewswire)
Aug-08-23 01:44PM	Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q2 2023 Earnings Call Transcript (Insider Monkey) +21.66%
Aug-07-23 04:51PM	Capricor: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-02-23 04:01PM	Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7 (GlobeNewswire)
Jul-24-23 08:30AM	Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors (GlobeNewswire)
Jul-13-23 08:30AM	Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors (GlobeNewswire)
Jul-06-23 12:27PM	The past five years for Capricor Therapeutics (NASDAQ:CAPR) investors has not been profitable (Simply Wall St.)
Jun-30-23 09:25AM	Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy (GlobeNewswire)
Jun-13-23 09:15AM	Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy (GlobeNewswire)
Jun-09-23 11:28AM	We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate (Simply Wall St.)
Jun-07-23 09:15AM	Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
May-13-23 09:18AM	Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shares Could Be 27% Above Their Intrinsic Value Estimate (Simply Wall St.)
May-11-23 04:22PM	Capricor: Q1 Earnings Snapshot (AP Finance)
04:01PM	Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-04-23 09:00AM	Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11 (GlobeNewswire)
Apr-27-23 09:00AM	Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX Platform (GlobeNewswire)
Mar-23-23 09:25AM	Capricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (GlobeNewswire)
Mar-20-23 11:27AM	When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Become Profitable? (Simply Wall St.)
Mar-18-23 03:12AM	Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-15-23 04:01PM	Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-08-23 09:00AM	Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15 (GlobeNewswire)
Mar-02-23 09:15AM	Capricor Therapeutics Receives Clinical Research Forums 2023 Top Ten Clinical Research Achievement Award (GlobeNewswire)
Feb-16-23 09:25AM	Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan (GlobeNewswire) +10.42%
Jan-25-23 08:00AM	Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients (GlobeNewswire)
Jan-19-23 04:05PM	Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program (GlobeNewswire) +8.75%
Jan-12-23 12:55PM	Capricor Highlights Preclinical Data From Its Closed COVID-19 Vaccine Study (Benzinga)
09:26AM	Capricor Announces Publication Highlighting New Advances for its Engineered Exosome Platform (GlobeNewswire)
Jan-11-23 12:00PM	Capricor (CAPR) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Dec-10-22 07:46AM	Despite shrinking by US$18m in the past week, Capricor Therapeutics (NASDAQ:CAPR) shareholders are still up 194% over 3 years (Simply Wall St.)
Nov-30-22 10:35AM	2 Strong Buy Penny Stocks That Could Rally All the Way to $15 (TipRanks) +11.19%
Nov-13-22 07:18AM	Capricor Therapeutics Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-10-22 05:15PM	Capricor Therapeutics (CAPR) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.14%
04:30PM	Edited Transcript of CAPR.OQ earnings conference call or presentation 10-Nov-22 9:30pm GMT (Thomson Reuters StreetEvents)
04:01PM	Capricor Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-03-22 04:01PM	Capricor Therapeutics to Present Third Quarter 2022 Financial Results and Recent Corporate Update on November 10 (GlobeNewswire)
Oct-06-22 09:00AM	Capricor Therapeutics to Present One-Year Results from HOPE-2 Open Label Extension Study at World Muscle Society 2022 (GlobeNewswire)
Sep-07-22 08:00AM	Capricor Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +5.57%
Aug-10-22 04:05PM	Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +16.81%
Aug-03-22 08:00AM	Capricor Therapeutics to Present Second Quarter 2022 Financial Results and Recent Corporate Update on August 10 (GlobeNewswire)
Jul-19-22 09:15AM	Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire) +5.25%
Jun-27-22 07:00AM	Capricor Therapeutics Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open Label Extension Study (GlobeNewswire)

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nippon Shinyaku Co Ltd	10% Owner	Sep 20 '24	Buy	5.36	2,798,507	14,999,998	7,090,351	Sep 24 04:01 PM
Musket David B	Director	Aug 07 '24	Option Exercise	1.39	34,000	47,260	81,692	Aug 09 09:00 AM
COLLIER EARL M JR	Director	Apr 23 '24	Option Exercise	1.39	30,000	41,700	56,856	Apr 25 09:15 AM
Musket David B	Director	Apr 23 '24	Option Exercise	1.39	16,156	22,457	47,692	Apr 24 01:30 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Oct 23 '23	Option Exercise	1.39	2,178	3,027	2,381	Oct 24 09:25 AM
Musket David B	Director	Oct 12 '23	Buy	2.75	410	1,128	31,536	Oct 13 01:59 PM
COLLIER EARL M JR	Director	Oct 10 '23	Buy	2.83	10,000	28,300	26,856	Oct 12 09:15 AM
Musket David B	Director	Oct 09 '23	Buy	2.82	5,083	14,334	31,126	Oct 11 09:15 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CAPR

Capricor Therapeutics Inc

Upgrade your FINVIZ experience